[{"id":"652d5ab0-cd46-459c-90cb-214f85150b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688881","created_at":"2021-01-18T13:06:49.957Z","updated_at":"2024-07-02T16:36:08.876Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02688881","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2022-06-15"}]